Whole-body PET/MRI in oncology: Current status and clinical applications

Clinical and Translational Imaging

Volumn 1, Issue 1, 2013, Pages 31-44

  Pace, Leonardo ^a   Nicolai, Emanuele ^b   Aiello, Marco ^b   Catalano, Onofrio Antonio ^b   Salvatore, Marco ^c  

^a UNIVERSITY OF SALERNO   (Italy)

^b IRCCS SDN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer imaging; Hybrid diagnostic systems; PET MRI; Tumor biology

Indexed keywords

DOTATOC GA 68; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; TRACER; UNCLASSIFIED DRUG;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DISTANT METASTASIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYBRID DIAGNOSTIC IMAGING; HYPOXIA; LYMPH NODE BIOPSY; META ANALYSIS (TOPIC); MOLECULAR IMAGING; ONCOLOGY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE TUMOR; TREATMENT RESPONSE; WHOLE BODY MRI; WHOLE BODY PET;

EID: 84890486066     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-013-0012-4     Document Type: Review

References (100)

1. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R et al (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41: 1369-1379.
2. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK (2002) PET diagnostic accuracy: improvement within-line PET-CT system: initial results. Radiology 225: 575-581.
3. Mittra E, Quon A (2009) PET/CT: the current technology and applications. Radiol Clin North Am 47: 147-160.
4. Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF (2010) FDG PET/CT in oncology: "raising the bar". Clin Radiol 65: 522-535.
5. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42(5 Suppl): 1S-93S.
6. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22(21): 4357-4368.
7. Von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238: 405-422.
8. Blodgett TM, Meltzer CC, Townsend DW (2007) PET/CT: form and function. Radiology 242: 360-385.
9. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G (2009) PET/CT for staging and follow-up of patients with malignancy. Eur J Radiol 70: 382-392.
10. Bettinardi V, Picchio M, Di Muzio N, Gianolli L, Messa C, Gilardi MC (2010) PET/CT for radiotherapy: image acquisition and data processing. Q J Nucl Med Mol Imaging 54(5): 455-475.
11. Seemann MD (2005) Whole-body PET/MRI: the future in oncological imaging. Technol Cancer Res Treat 4: 577-582.
12. Zaidi H, Mawlawi O, Orton CG (2007) Simultaneous PET/MR will replace PET/CT as the molecular multimodality imaging platform of choice. Med Phys 34: 1525-1528.
13. von Schulthess GK, Schlemmer HPW (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(Suppl. 1): S3-S9.
14. Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, Marsden PK (1997) Simultaneous PET and MR imaging. Phys Med Biol 42: 1965-1970.
15. Delso G, Ziegler S (2009) PET/MRI system design. Eur J Nucl Med Mol Imaging 36(suppl 1): S86-S92.
16. Herzog H (2012) PET/MRI: challenges, solutions and perspectives. Z Med Phys 22: 281-298. doi: 10. 1016/j. zemedi. 2012. 07. 003.
17. Yoon HS, Ko GB, Kwon SI, Lee CM, Ito M, Chan Song I, Lee DS, Hong SJ, Lee JS (2012) Initial results of simultaneous PET/MRI experiments with an MRI-compatible silicon photomultiplier PET scanner. J Nucl Med 53: 608-614.
18. Zaid H, Del Guerra A (2011) An outlook on future design of hybrid PET/MRI systems. Med Phys 38: 5667-5689.
19. Kops ER, Herzog H (2007) Alternative methods for attenuation correction for PET images in MR-PET scanners. IEEE Nucl Sci Symp Conf Rec 6: 4327-4330.
20. Zaidi H, Montandon M, Slosman DO (2003) Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys 30: 937-948.
21. Hofmann M, Steinke F, Scheel V, Charpiat G, Farquhar J, Aschoff P, Brady M, Schölkopf B, Pichler BJ (2008) MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med 49: 1875-1883.
22. Hofmann M, Bezrukov I, Mantlik F, Aschoff P, Steinke S, Beyer T, Pichler BJ, Bernhard Scholkopf B (2011) MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med 52: 1392-1399.
23. Martinez-Möller A, Nekolla SG (2012) Attenuation correction for PET/MR: problems, novel approaches and practical solutions. Z Med Phys 22: 299-310. doi: 10. 1016/j. zemedi. 2012. 08. 003.
24. Schlemmer HP, Pichler BJ, Schmand M, Burbar Z, Michel C, Ladebeck R, Jattke K, Townsend D, Nahmias C, Jacob PK, Heiss WD, Claussen CD (2008) Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248: 1028-1035.
25. 18F-FDG PET/CT. Nuklearmedizin 46(1): 9-14.
26. Babin E, Desmonts C, Hamon M, Bénateau H, Hitier M (2008) PET/CT for assessing mandibular invasion by intraoral squamous cell carcinomas. Clin Otolaryngol 33(1): 47-51.
27. Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, Börsch G, Dahmen G, Barkhausen J, Bockisch A, Antoch G (2006) Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 296(21): 2590-2600.
28. 18FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol 17(11): 1427-1433.
29. Boss A, Stegger L, Bisdas S, Kolb A, Schwenzer N, Pfister M, Claussen CD, Pichler BJ, Pfannenberg C (2011) Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol 21: 1439-1446.
30. Nakamoto Y, Tamai K, Saga T, Higashi T, Hara T, Suga T, Koyama T, Togashi K (2009) Clinical value of image fusion from MR and PET in patients with head and neck cancer. Mol Imaging Biol 11: 46-53.
31. Kuhl C (2007) The current status of breast MR imaging. Part 1. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 244: 356-378.
32. 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions. Am J Roentgenol 191(5): 1323-1330.
33. Moy L, Noz ME, Maguire GQ Jr, Melsaether A, Deans AE, Murphy-Walcott AD, Ponzo F (2010) Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J 16: 369-376.
34. Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Boy C, Forsting M, Bockisch A, Antoch G, Stahl A (2011) Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 52: 1009-1014.
35. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 49: 1912-1921.
36. Kam MH, Wong DC, Siu S, Stevenson AR, Lai J, Phillips GE (2010) Comparison of magnetic resonance imaging-fluorodeoxy-glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg 97: 266-268.
37. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D (2010) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5): 204-213.
38. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE (2007) Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 245: 839-847.
39. Sinha S, Peach AH (2010) Diagnosis and management of soft tissue sarcoma. BMJ 341: c7170.
40. Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, Murakami K, Terauchi T, Suga T, Inoue T, Kim EE (2009) Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 23: 155-161.
41. Thorwarth D, Leibfarth S, Monnich D (2013) Potential role of PET/MRI in radiotherapy treatment planning. Clin Transl Imaging. doi: 10. 1007/s40336-013-0006-2.
42. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.
43. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD; Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25: 571-578.
44. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol 81: 303-311.
45. Punwani S, Taylor SA, Bainbridge A, Prakash V, Bandula S, De Vita E, Olsen OE, Hain SF, Stevens N, Daw S, Shankar A, Bomanji JB, Humphries PD (2010) Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 255: 182-190.
46. Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P, Lin SJ, Belhadj K, Brugières P, Evangelista E, Haioun C, Meignan M, Rahmouni A (2010) Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 20: 2027-2038.
47. 18F-FDG PET/CT. AJR 196: 662-669.
48. 18F-FDG PET/MRI for staging and restaging in paediatric oncology. Eur J Nucl Med Mol Imaging 39: 1745-1755.
49. Collins CD (2007) PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging 7(Spec No A): S77-S87.
50. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290: 3199-3206.
51. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, Brown G, McLeod R, Kennedy E (2012) Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 19: 2212-2223.
52. 18F-FDGPET/CT. J Comput Assist Tomogr 35: 531-534.
53. Volker T, Denecke T, Steffen I et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25: 5435-5441.
54. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO Guidelines Working Group (2010) Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5): v194-v197.
55. Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, Schoenberg SO (2008) Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1. 5 and 3 T compared to FDG-PET-CT. Eur J Radiol 65(1): 47-58.
56. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43: 557-564.
57. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17: 939-949.
58. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO (2005) High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 40: 743-753.
59. Liu J, Yang X, Li F, Wang X, Jiang X (2011) Preliminary study of whole-body diffusion-weighted imaging in detecting pulmonary metastatic lesions from clear cell renal cell carcinoma: comparison with CT. Acta Radiol 52: 954-963.
60. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 46: 548-555.
61. 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med 51: 692-699.
62. 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21: 2604-2617.
63. 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 40: 523-531.
64. 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 81: 1007-1015.
65. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
66. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45: 228-247.
67. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1): 122S-150S.
68. Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50: 1S-10S.
69. Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, van Cutsem E et al (2012) Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys 82: 863-870.
70. Dong S, Ye XD, Yuan Z, Xu LC, Xiao XS (2012) Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization. Eur J Radiol 81: 472-477.
71. Vandecaveye V, Dirix P, De Keyzer F, Op de Beeck K, Vander Poorten V, Hauben E, Lambrecht M, Nuyts S, Hermans R (2012) Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 82: 1098-1107.
72. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T (2010) Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 49: 354-360.
73. Chen JH, Bahri S, Mehta RS, Kuzucan A, Yu HJ, Carpenter PM, Feig SA, Lin M, Hsiang DJ, Lane KT, Butler JA, Nalcioglu O, Su MY (2011) Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3. 0-T MR imaging. Radiology 261: 735-743.
74. Ueda S, Tsuda H, Saeki T, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Omata J, Moriya T, Fukatsu K, Yamamoto J (2010) Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J 16: 660-662.
75. Bolog N, Pfammatter T, Mullhaupt B, Andreisek G, Weishaupt D (2008) Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization. Abdom Imaging 33: 313-323.
76. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 16: 80-87.
77. Park MJ, Kim SH, Lee SJ, Jang KM, Rhim H (2011) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology 260: 771-780.
78. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1): 43S-54S.
79. Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119: 2066-2073.
80. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52: 386-392.
81. Lin C, Itti E, Luciani A, Zegai B, Lin SJ, Kuhnowski F, Pigneur F, Gaillard I, Paone G, Meignan M, Haioun C, Rahmouni A (2011) Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol 46: 341-349.
82. Inaoka T, Takahashi K, Mineta M, Yamada T, Shuke N, Okizaki A, Nagasawa K, Sugimori H, Aburano T (2007) Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology 243: 869-876.
83. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51: 1198-1205.
84. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 71: 242-248.
85. 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging 38: 1862-1868.
86. Verma S, Rajesh A (2011) A clinically relevant approach to imaging prostate cancer: review. Am J Roentgenol 196(3 Suppl): S1-S10.
87. 11C-choline. J Nucl Med 52: 81-89.
88. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, Chenevert T, Piert M (2012) Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med 53: 546-551.
89. 11C-acetate PET/CT. Eur J Radiol 81: 2966-2972. doi: 10. 1016/j. ejrad. 2011. 12. 043.
90. Nanni C, Fantini L, Nicolini S, Fanti S (2010) Non FDG PET. Clin Radiol 65: 536-548.
91. 18F)FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 52: 50-65.
92. Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16(11): 508-515.
93. Ziegler SI, Delso G (2013) Technical and methodological aspects of PET/MRI. Clin Transl Imaging. doi: 10. 1007/s40336-013-0011-5.
94. Eiber M, Martinez-Möller A, Souvatzoglou M, Holzapfel K, Pickhard A, Löffelbein D, Santi I, Rummeny EJ, Ziegler S, Schwaiger M, Nekolla SG, Beer AJ (2011) Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging 38: 1691-1701.
95. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53(6): 845-855. doi: 10. 2967/jnumed. 111. 098608.
96. Wiesmüller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, Schmidt D, Beck M, Kuwert T, von Gall CC (2013) Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging 40: 12-21.
97. Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Langner J, Schramm G, Laniado M, Kotzerke J, van den Hoff J (2013) PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 40: 6-11.
98. Akbarzadeh A, Ay MR, Ahmadian A, Riahi Alam N, Zaidi H (2013) MRI-guided attenuation correction in whole-body PET/MR: assessment of the effect of bone attenuation. Ann Nucl Med 27(2): 152-162.
99. Kim JH, Lee JS, Song IC, Lee DS (2012) Comparison of segmentation-based attenuation correction methods for PET/MRI: evaluation of bone and liver standardized uptake value with oncologic PET/CT data. J Nucl Med 53: 1878-1882.
100. Martinez-Moller A, Eiber M, Nekolla SG, Souvatzoglou M, Drzezga A, Ziegler S, Rummeny EJ, Schwaiger M, Beer AJ (2012) Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med 53: 1415-1426.